The modulatory hematopoietic activities of leukemia inhibitory factor. Leuk Lymphoma 1992 Sep;8(1-2):1-7
Date
09/01/1992Pubmed ID
1493463DOI
10.3109/10428199209049811Scopus ID
2-s2.0-0026699346 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Leukemia inhibitory factor (LIF) is a multi-potential cytokine which has been implicated in the hematopoietic regulatory machinery. For example, we have found that LIF is constitutively expressed in marrow stroma. Other investigators have reported that LIF affects remodeling of bone, and that, in concert with other growth factors, it stimulates hematopoietic stem cell proliferation. Moreover, in vivo animal trials reveal that, at high doses, administration of LIF induces myelosclerosis whereas, at lower doses, megakaryocytosis and thrombocytosis with reduced bone marrow cellularity and marrow lymphopenia are observed. Therefore, the role of LIF in the pathogenesis of myeloproliferative disorders such as myelofibrosis and sclerosis merits investigation. Further, its megakaryocytic stimulatory properties suggest that LIF may be exploitable in the clinic to enhance platelet production.
Author List
Estrov Z, Talpaz M, Wetzler M, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsGrowth Inhibitors
Hematopoiesis
Humans
Interleukin-6
Leukemia Inhibitory Factor
Lymphokines
